The merger of Pfizer and Wyeth is expected to create the second-biggest drug maker among multinational companies in India. The world's largest drug maker Pfizer yesterday announced a $68-billion acquisition of US-based Wyeth.
Ajit Mishra, vice president, research, Religare Broking, answers your queries.
The letter was the latest sign of US frustration about the business environment in India.
Markets recovered in late trades, amid firm European cues, led by rebound in financials and gains in IT shares.
The company now plans to bet on health sciences, skin care and specialised products, says Arnab Dutta.
Today, apologies by CEOs of global corporations have become so common that you get case studies on the subject.
Sun Pharma and Dr Reddy's top list in terms of those who face most class-action litigation
The 30-share Sensex ended down 32 points at 28,851 and the 50-share Nifty closed 12 points lower at 8,712.
India and the US on Sunday agreed to enhance their engagement on intellectual property rights, a vexed issue between the two countries.
Supreme Court will give its verdict on April 1 on whether Swiss giant Novartis AG's cancer treatment drug Glivec deserves a patent in the country not it doesn't.
Modi urged the Swiss business leaders to explore the investment opportunities in India.
In spite of all their complaints, pharma MNCs have been gaining market share in India. And this growth has come largely with generics.
Nifty50 surged 87 points to end at 8,157, highest closing levels since Oct 29, 2015.
People die from diseases like AIDS, TB, etc because life saving essential medicines are either too expensive, or not available because they are not seen as financially viable.
Closure would mean manufacturer might not be able to launch any new generic products in India in future.
Seeking to minimise the impact of the recent headline-grabbing moves, he said there had only been one instance of compulsory licensing.
Eight commonly prescribed anti-cancer drugs will soon enter India's National List of Essential Medicines (NLEM).
The ministry has asked 44 pharmaceutical companies, including global drug majors such as Eli Lilly, Novartis, Pfizer, Bayer, Merck, Johnson & Johnson and Sanofi Aventis, to explain why they have not given the compensation, which is mandatory under the current drug laws.
India's Supreme Court in April rejected a patent for Novartis AG's cancer drug Glivec, saying it was an amended version of a known molecule called imatinib, setting the precedent for more such cases in the country.
Delegation visit ahead of patent law report.
The footprints of Indian-origin corporate executives at multinationals is expanding, with Sandeep Kataria taking over the reins of footwear major Bata as its global chief executive officer. From FMCG majors to IT titans, Kataria joins the league of Indian-origin executives who have climbed the highest echelons of corporate across diverse sectors globally. From Nooyi to Pichai to Nadella, the list of such people at the helm of multi-billion dollar enterprises is long.
Investors accumulated quality stocks at valuable and attractive levels.
The Clinical Research sector is emerging as an attractive option for science graduates, doctors, management/ IT professionals, alike.
These include former drugs controller M Venkateshwarlu, Ranbaxy CMD Malvinder Mohan Singh, Ranjit Shahani, India chief of Swiss pharma major Novartis AG, Ramaprasad Reddy, chairman Aurobindo Pharma and Rajesh Jain, joint managing director, Panacea Biotec.
This has prompted public health groups to call the concerns of Swiss drug major Novartis that inadequacies in Indian patent law will have negative consequences for patients and public health in India as 'bogus'.
A recent report has suggested that future patent expires in the cardiac and anti-diabetes space would form a good opportunity for smaller firms, given their franchise in these segments.
Special 301 Report expresses concern over weak IPR laws, to conduct reviews.
To ensure equal access to health care, the government must consider it in a holistic manner and improve all parameters.
Most foreign drug makers have 100% subsidiaries in India, apart from their listed arms.
Abbott Laboratories is suing India's Ranbaxy Laboratories as well as Israel's Teva and Sandoz of the Novartis group, in Chicago for allegedly violating its patents protecting Omnicef, a drug used to treat ear, throat and skin infections.
India's biggest drug maker Ranbaxy Laboratories Ltd has put in its bid to acquire generic business of German pharmaceutical firm Merck.
Eminent Indian-origin academician Srikant Datar has been named as Dean of Harvard Business School, succeeding Nitin Nohria and becoming the second consecutive dean hailing from India to lead the prestigious 112-year-old institution. Datar, an alumnus of University of Bombay and Indian Institute of Management, Ahmedabad, is the Arthur Lowes Dickinson Professor of Business Administration and the senior associate dean for University Affairs at Harvard Business School (HBS). He will assume charge as the school's next dean on January 1, president Larry Bacow said.
Investors must carefully watch the developments on the MNC pipeline.
The 1995 judgment in the Union of India vs Cricket Association of Bengal case emphasised that free speech is essential for a successful democracy and citizens must have a plurality of views and a range of opinions on all public issues, says M J Antony.
An insider said that over the past decade or so Cipla has become immune to the exits of leaders. There have been no directional change in the long-term strategies.
Data exclusivity key building block for R&D investment, says Novartis.
Like pharmaceutical companies globally - which used to enjoy a preferential exchange rate in Venezuela - Indian producers have been left badly stung by the collapse of the bolivar currency
Broader markets are outperforming the benchmark indices- BSE Midcap and Smallcap indices are up 0.8%-1%.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances